2017 Symposium Highlights Notable Research Advances in Genitourinary Cancers

For immediate release
February 15, 2017


Alise Fisher

ORLANDO – Five studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2017 Genitourinary Cancers Symposium, taking place February 16-18 at Rosen Shingle Creek in Orlando, Florida. These noteworthy abstracts investigate several approaches to the treatment and management of prostate cancer, bladder cancer, and advanced kidney cancer.

Experts in genitourinary cancers are available to comment on the studies below.

Abstract 132:
Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza).

Poster Session A
Thursday, February 16, 2017: 11:30 AM - 1:00 PM EST
Thursday, February 16, 2017:  5:15 PM - 6:15 PM EST Rosen, Gatlin Ballroom B, Level 1

John L. Silberstein, MHS
The James Buchanan Brady Urological Institute,
The Johns Hopkins Hospital
Baltimore, Maryland


Abstract 141:
Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.

Poster Session A
Thursday, February 16, 2017: 11:30 AM - 1:00 PM EST
Thursday, February 16, 2017:  5:15 PM - 6:15 PM EST Rosen, Gatlin Ballroom B, Level 1

Joaquin Mateo, MD
The Institute of Cancer Research & The Royal Marsden
London, United Kingdom


Abstract 280:
BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.

Oral Abstract Session B
Friday, February 17, 2017: 1:45 PM - 1:55 PM EST
Rosen, Gatlin Ballroom C, Level 1

Emma Hall, PhD
Clinical Trials and Statistics Unit,
The Institute of Cancer Research
London, United Kingdom


Abstract 431:
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).

Poster Session C
Saturday, February 18, 2017: 7:00 AM – 7:55 AM EST
Saturday, February 18, 2017: 11:30 AM  - 1:00 PM EST Rosen, Gatlin Ballroom B, Level 1

David McDermott, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts


Abstract 434:
Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).

Oral Abstract Session C
Saturday, February 18, 2017: 1:35 PM – 1:45 PM EST
Rosen, Gatlin Ballroom C, Level 1

Sumanta K. Pal, MD
City of Hope
Duarte, California


2017 Gastrointestinal Cancers Symposium News Planning Team
Sumanta K. Pal, MD, American Society of Clinical Oncology (ASCO); Daniel A. Hamstra, MD, PhD, American Society for Radiation Oncology (ASTRO); and Marc Dall’Era, MD, Society of Surgical Oncology (SSO)



About the American Society for Radiation Oncology:
The American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologist, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology, Biology, PhysicsPractical Radiation Oncology, and Advances in Radiation Oncology, developed and maintains an extensive patient website; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. Learn more about ASTRO.

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

About the Society of Urologic Oncology:
The Society of Urologic Oncology (SUO) was created in 1984 to enable qualified members primarily interested in the care of patients with malignant genitourinary diseases to meet for the purpose of discussion, development, and implementation of ideas to improve care. The Society and its bylaws conform to the guidelines and bylaws of the American Urological Association (AUA).

The purpose of the SUO is to develop educational and research initiatives and to study issues in urologic oncology and provide physician statements that represent a state of the art assessment of these issues to other organizations.

The Society also provides a forum for identifying the urologic oncologist as a physician with specific expertise in the study and treatment of genitourinary malignancies. In recognition of the multidisciplinary efforts involved in the study and treatment of genitourinary malignancies, the Society seeks to incorporate multiple disciplines in achieving these goals. The Society supports the activities of multiple disciplines in the common objectives of seeking an increased understanding and successful treatment of genitourinary malignancies.

The SUO seeks to improve the care of patients with malignant urologic disease and to provide a forum for the discussion of problems relating to malignant urologic disease. Our objectives include: 1) Stimulating research in and the teaching of urologic oncology, 2) Disseminating the principles of urologic oncology to the medical profession at large, 3) Bringing urologists into a Society whose work is entirely, or principally with malignant disease, 4) Being identified as the most qualified organization on matters relating to urologic oncology, and 5) Standardize fellowship training in urologic oncology.

Please visit our website, suonet.org or call (847) 264-5901 for more information on how to become a member.